Yuhan’s Leclaza zooms through the NHI listing process

By Eo, Yun-Ho | translator Byun Kyung A

21.01.25 19:06:22

가나다라 0

Cancer Deliberation Committee to review in February, immediately after marketing authorization

Lung Cancer Association urges for coverage, presumably listing and pricing to be processed fast

Yuhan Corporation’s new drug Leclaza could break the record of receiving the National Health Insurance reimbursement the fastest as an anticancer treatment. After the South Korean health authority approved of the drug on Jan. 18, the company immediately entered a talk to list the drug.

The pharmaceutical industry source reported the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee is to deliberate Leclaza (lazertinib), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) like Tagrisso (osimertinib), from next month.

Yuhan Corporation is rushing through the commercialization process by fully utilizing the conditio

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)